Breaking News

Richter-Helm Triples cGMP Production Capacity

Will invest close to €70 million to triple current biologic production capacity and expand existing warehouse, lab, and administration buildings.

Richter-Helm BioLogics GmbH & Co. KG, a German CDMO, began construction for an expansion at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biologics manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023.
 
The basic engineering of the new facility has been completed and the ground-breaking ceremony took place on May 5th, 2021 by the management team of Richter-Helm, who initiated construction of the new facility.
 
Richter-Helm and its affiliated companies Gedeon Richter and HELM AG will invest close to €70 million to triple current production capacity and expand its existing warehouse, lab, and administration buildings.
 
Currently, Richter-Helm operates two cGMP production facilities in Hannover and Bovenau, Germany, with bioreactor capacities of up to 1,500 litres. The Bovenau expansion covers installment of two additional highly flexible and fully equipped production trains with interchangeable product flows. Bioreactor capacities of 300 litres and 1,500 litres will be added. The production site will reach a total area of about 10,000 m² and includes all necessary utilities and infrastructure, like QC-labs, warehouse and technical areas.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters